Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Eprinomectin, a novel semi-synthetic macrocylic lactone is cytotoxic to PC3 metastatic prostate cancer cells via inducing apoptosis

Toxicology and Applied Pharmacology(2020)10.1016/j.taap.2020.115071Source: DataRank Database

Eprinomectin, a novel semi-synthetic macrocylic lactone is cytotoxic to PC3 metastatic prostate cancer cells via inducing apoptosis is a research paper published in Toxicology and Applied Pharmacology (2020). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)OA: greenTopics (29)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Velavan Bakthavachalam,Mona Vudutha,Smita Vinjamuri,Somaiah Chinnapaka,Gnanasekar Munirathinam ORCID

Live enrichment

PubMed:32454055 PMC:PMC7716802

National Institutes of Health

Grant: R03 CA230829

National Institutes of Health

Grant: R03 CA227218

National Institutes of Health

Grant: R03 CA212890

National Institutes of Health

Grant: 1R03CA227218-01

Dietary management of castration-resistant prostate cancer

National Institutes of Health

Grant: 1R03CA230829-01

Targeting TCTP Signaling to Control Castration-Resistant Prostate Cancer

National Institutes of Health

Grant: 1R03CA212890-01A1

Overcoming EMT-driven metastatic castration-resistant prostate cancer

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7716802

publisherhttps://api.elsevier.com/content/article/PII:S0041008X20301952?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0041008X20301952?httpAccept=text/plain

https://doi.org/10.1016/j.taap.2020.115071

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716802

Fields of Study

0301 basic medicine03 medical and health sciences

MeSH Terms

HumansProstatic NeoplasmsReactive Oxygen SpeciesLactonesIvermectinMacrocyclic CompoundsAntineoplastic AgentsCytotoxinsApoptosisDose-Response Relationship, DrugMalePC-3 Cells

Keywords

ApoptosisStem Cellsprostate cancerEprinomectinMaleIvermectinMacrocyclic CompoundsDose-Response Relationship, DrugCytotoxinsProstatic NeoplasmsAntineoplastic AgentsLactonesPC-3 CellsHumansReactive Oxygen Species

Sustainable Development Goals

SDG 3: 3. Good health

Eprinomectin, a novel semi-synthetic macrocylic lactone is cytotoxic to PC3 metastatic prostate cancer cells via inducing apoptosis

FAIR Checklist

Authors (6)

Funding (6 grants)

Open Access

Topics

Annotations (Europe PMC)